Filtered By:
Drug: Gilenya

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 88 results found since Jan 2013.

Fingolimod Protects Against Ischemic White Matter Damage by Modulating Microglia Toward M2 Polarization via STAT3 Pathway Basic Sciences
Conclusions—Our study suggested that FTY720 might be a potential therapeutic drug targeting brain inflammation by skewing microglia toward M2 polarization after chronic cerebral hypoperfusion.
Source: Stroke - November 27, 2017 Category: Neurology Authors: Chuan Qin, Wen-Hui Fan, Qian Liu, Ke Shang, Madhuvika Murugan, Long-Jun Wu, Wei Wang, Dai-Shi Tian Tags: Ischemic Stroke, Vascular Disease Original Contributions Source Type: research

Fingolimod promotes angiogenesis and attenuates ischemic brain damage via modulating microglial polarization.
CONCLUSIONS: Our research indicated that FTY720 treatment promoted angiogenesis via microglial M2 polarization and exerted neuroprotection in PT ischemic stroke. PMID: 31626784 [PubMed - as supplied by publisher]
Source: Brain Research - October 14, 2019 Category: Neurology Authors: Shang K, He J, Zou J, Qin C, Lin L, Zhou LQ, Yang LL, Wu LJ, Wang W, Zhan KB, Tian DS Tags: Brain Res Source Type: research

Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation
Abstract Sphingosine-1-phosphate (S1P) and S1P receptors (S1PR) are ubiquitously expressed. S1P-S1PR signaling has been well characterized in immune trafficking and activation in innate and adaptive immune systems. However, the full extent of its involvement in the pathogenesis of autoimmune diseases is not well understood. FTY720 (fingolimod), a non-selective S1PR modulator, significantly decreased annualized relapse rates in relapsing-remitting multiple sclerosis (MS). FTY720, which primarily targets S1P receptor 1 as a functional antagonist, arrests lymphocyte egress from secondary lymphoid tissues and reduce...
Source: Drugs - June 17, 2016 Category: Drugs & Pharmacology Source Type: research

The impact of fingolimod on Treg function in brain ischaemia
In conclusion, fingolimod seems to improve the suppressive function of Treg post-stroke while also increasing the resistance of CD4+ effector cells to this suppression. Fingolimod's capacity to increase both effector and regulatory functions may explain the lack of consistent improvement in functional recovery in experimental brain ischaemia.PMID:37366289 | DOI:10.1002/eji.202350370
Source: European Journal of Immunology - June 27, 2023 Category: Allergy & Immunology Authors: Kyle Malone Jennifer A Shearer Christian Waeber Anne C Moore Source Type: research

A Case Of Hemophagocytic Lymphohistiocytosis Syndrome In A Patient With Multiple Sclerosis On Fingolimod Therapy. (P2.206)
CONCLUSIONS:As far as we know, this syndrome has never been reported in fingolimod treated patients. EBV reactivation may have been the triggering factor of HLH in our patient. Whether fingolimod contributed to HLH, through a direct mechanism, or indirectly favoring EBV reactivation, remains unknown. Our case highlights the diagnostic challenge of HLH and the need of monitoring and reporting serious adverse events in patients exposed to new IMD. Study Supported by:Disclosure: Dr. Abreu has received personal compensation for activities with Bayer Pharmaceuticals Corporation, Novartis, and Biogen Idec. Dr. Peixoto has nothin...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Abreu, P., Peixoto, C., Carvalho, C., Santos, L., Sarmento, A., Jose Sa, M. Tags: MS and CNS Inflammatory Disease: Treatment Safety Source Type: research

Reversible Cerebral Vasoconstriction Syndrome and Fingolimod: Culprit or Innocent Bystander (P2.224)
CONCLUSIONS:Reversible cerebral vasoconstriction syndrome may be a rare complication of Fingolimod treatment and should be considered in patients with new onset thunderclap headache. The mechanism likely involves the effects of Fingolimod on S1P(3) receptors on cerebral arteries.Disclosure: Dr. Fleming has nothing to disclose. Dr. West has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Fleming, J., West, M. Tags: MS and CNS Inflammatory Disease: Treatment Safety Source Type: research

Stroke Rounds: An MS Drug for ICH?
(MedPage Today) -- Patients with intracerebral hemorrhage showed improved outcomes when given fingolimod (Gilenya), the oral multiple sclerosis drug, compared with standard care alone in a small trial, researchers said.
Source: MedPage Today Primary Care - July 8, 2014 Category: Primary Care Source Type: news

Protective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage
Background: Subarachnoid hemorrhage (SAH) is a neurological emergency with limited pharmacological treatment options. Inflammation is increasingly recognized as a key pathogenic contributor to brain injury in this condition. In the present study, we examined the neuroprotective effects of the immunomodulatory agent, fingolimod, in rats subjected to SAH. Methods: We utilized an endovascular rat perforation model of SAH. Animals were divided into four groups: (1) sham-vehicle; (2) sham-fingolimod; (3) SAH-vehicle; and (4) SAH-fingolimod. Rats received either vehicle solution or fingolimod (0.5 mg/kg) intraperitoneally 3 hour...
Source: Journal of Neuroinflammation - January 27, 2015 Category: Neurology Authors: Hao-Liang XuDale PelligrinoChanannait PaisansathanFernando Testai Source Type: research

Treatment with FTY720 has no beneficial effects on short-term outcome in an experimental model of intracerebral hemorrhage
Conclusions Our results suggest that FTY720 has no beneficial effects in the acute phase of experimental ICH.
Source: Experimental and Translational Stroke Medicine - February 18, 2016 Category: Neurology Source Type: research

What Genetics are Associated with Multiple Sclerosis?
Discussion Multiple sclerosis (MS) is “a chronic degenerative, often episodic disease of the central nervous system marked by patchy destruction of the myelin that surrounds and insulates nerve fibers, usually appearing in young adulthood and manifested by one or more mild to severe neural and muscular impairments, as spastic weakness in one or more limbs, local sensory losses, bladder dysfunction, or visual disturbances.” It is a chronic disease and therefore symptoms must occur more than once. The first episode is called an acute demyelinating attack. Fifteen to forty-five percent of children with their first...
Source: PediatricEducation.org - April 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Mechanism of Action and Clinical Potential of Fingolimod for the Treatment of Stroke
Wentao Li, Haoliang Xu, Fernando D. Testai
Source: Frontiers in Neurology - August 25, 2016 Category: Neurology Source Type: research

Blockage of central sphingosine-1-phosphate receptor does not abolish the protective effect of FTY720 in early brain injury after experimental subarachnoid hemorrhage.
CONCLUSION: The present study suggests that systemic administration of FTY720 reduces EBI after SAH and that the effect might not come from central S1P activation but be associated with peripheral effects such as immunomodulation. PMID: 27605019 [PubMed - as supplied by publisher]
Source: Current Drug Delivery - September 5, 2016 Category: Drugs & Pharmacology Authors: Hasegawa Y, Uekawa K, Kawano T, Suzuki H, Kim-Mitsuyama S Tags: Curr Drug Deliv Source Type: research

Fingolimod Confers Neuroprotection through Activation of Rac1 after Experimental Germinal Matrix Hemorrhage in Rat Pups
This article is protected by copyright. All rights reserved.
Source: Journal of Neurochemistry - December 31, 2016 Category: Neurology Authors: William B. Rolland, Paul R. Krafft, Tim Lekic, Damon Klebe, Julia LeGrand, Abby Jones Weldon, Liang Xu, John H. Zhang Tags: Original Article Source Type: research